Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel

 
• By Sue Sutter

The Endocrinologic and Metabolic Drugs Advisory Committee majority says new studies should validate the proposed risk mitigation measures before approval for T1D.

Scales
The risks of insulin icodec outweigh its benefits in type 1 diabetes, the adcomm said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers